HR Pharmaceuticals, Inc. (HRP) announced that they have entered into an Exclusive Commercial Agreement with Poiesis Medical LLC, under which HRP will license Poiesis's Dual Balloon Catheter (Duette™).
Fresenius Kabi announced it has signed a multiyear agreement under which the Mayo Clinic is expected to purchase 10,000 Ivenix® large-volume infusion pumps for its hospitals and clinics in Minnesota, Arizona and Florida.
Octapharma USA announced the expansion of the U.S. Food and Drug Administration (FDA) approval for wilate®, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection.
West Pharmaceutical Services, Inc. a global leader in innovative solutions for injectable drug administration systems, announced FDA 510(k) clearance and launch of its Vial2Bag Advanced® 13mm admixture device.
Hovione, the specialist integrated CDMO and the leader in spray drying and particle engineering, announced it has acquired ExtremoChem Lda (ExtremoChem), an innovative start-up company focused on the synthesis, development, and commercialization of bio-inspired synthetic sugars, targeting enhanced stabilization, reduced viscosity and delivery performance of proteins and other biopharmaceuticals.
Stevanato Group a leading global provider of drug containment and delivery solutions to the pharmaceutical, biotechnology, and life science industries, announced that its Mavis™ Combi visual inspection machine has been selected as a winner of the 2023 Pharma Innovation Awards by Pharma Manufacturing, a brand of Endeavor Business Media.
Daewoong Pharmaceutical announced on the 6th that it will commence full-scale development of an obesity treatment utilizing a microneedle patch loaded with GLP-1 (Glucagon-like peptide-1) analogues.
BioCina Pty Ltd., a global end-to-end biologics contract development and manufacturing organization (CDMO), announced the expansion of their partnership with GPN Vaccines Ltd.
Edwards Lifesciences announced it received CE Mark for the MITRIS RESILIA valve, a tissue valve replacement specifically designed for the heart's mitral position.
Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products announced successful completion of the nonclinical development phase of Focal Medical’s Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003).